{"id":"endostar-cisplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Bleeding"}]},"_chembl":{"chemblId":"CHEMBL197201","moleculeType":"Small molecule","molecularWeight":"520.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Endostar (rh-endostatin) is an angiogenesis inhibitor derived from the C-terminal fragment of collagen XVIII. It suppresses tumor neovascularization by inhibiting endothelial cell proliferation and migration, thereby starving tumors of blood supply. When combined with cisplatin, a platinum-based chemotherapy agent that causes DNA damage, the dual mechanism targets both tumor vasculature and cancer cells directly.","oneSentence":"Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation, used in combination with cisplatin chemotherapy to treat solid tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:50.983Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (in combination with cisplatin)"},{"name":"Advanced solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT04914598","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-07-28","conditions":"Malignant Pleural Effusion","enrollment":290},{"nctId":"NCT06562673","phase":"PHASE1, PHASE2","title":"Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma","status":"COMPLETED","sponsor":"Shanghai 6th People's Hospital","startDate":"2024-12-03","conditions":"Osteosarcoma, Bone Cancer","enrollment":10},{"nctId":"NCT03086681","phase":"PHASE2","title":"Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma","status":"COMPLETED","sponsor":"Yong Zhang,MD","startDate":"2017-04-20","conditions":"Cervical Carcinoma","enrollment":120},{"nctId":"NCT03797625","phase":"PHASE2","title":"Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas","status":"COMPLETED","sponsor":"Fudan University","startDate":"2017-05-04","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":52},{"nctId":"NCT05879796","phase":"","title":"Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2023-05-16","conditions":"Cervical Cancer","enrollment":30},{"nctId":"NCT05574998","phase":"PHASE2","title":"First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2021-02-01","conditions":"Non-Small-Cell Lung Cancer","enrollment":100},{"nctId":"NCT02749526","phase":"PHASE2","title":"Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial","status":"TERMINATED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-04","conditions":"Esophageal","enrollment":70},{"nctId":"NCT04447326","phase":"PHASE2","title":"Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2020-06","conditions":"Nasopharyngeal Carcinoma","enrollment":106},{"nctId":"NCT02444949","phase":"PHASE2","title":"A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"China Three Gorges University, Yichang, China","startDate":"2014-06","conditions":"Nasopharyngeal Neoplasms","enrollment":75},{"nctId":"NCT04094909","phase":"PHASE2","title":"Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2020-02-06","conditions":"Staging IV NSCLC","enrollment":186},{"nctId":"NCT04121975","phase":"PHASE2","title":"CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-08-01","conditions":"Cervical Cancer","enrollment":82},{"nctId":"NCT03932266","phase":"PHASE2","title":"Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2019-06","conditions":"Nasopharyngeal Carcinoma","enrollment":73},{"nctId":"NCT02902432","phase":"PHASE2","title":"A Trial of Endostar in Patients With Carcinoma of the Head and Neck","status":"UNKNOWN","sponsor":"China International Medical Foundation","startDate":"2016-06","conditions":"Nasopharyngeal Neoplasms","enrollment":24},{"nctId":"NCT01669707","phase":"PHASE2","title":"Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2011-04","conditions":"Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT03622827","phase":"PHASE2","title":"Postoperative Concurrent Chemoradiotherapy Combined With Endostar for High-risk Early Stage Cervical Cancer","status":"UNKNOWN","sponsor":"Nanjing Medical University","startDate":"2018-07-31","conditions":"Uterine Cervical Neoplasms","enrollment":120},{"nctId":"NCT03588494","phase":"PHASE2, PHASE3","title":"Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Affiliated Hospital of North Sichuan Medical College","startDate":"2018-08-01","conditions":"Quality of Life","enrollment":318},{"nctId":"NCT03123445","phase":"PHASE2","title":"Endostar First-line Treatment of Advanced NSCLC","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2017-04","conditions":"Non Small Cell Lung Cancer","enrollment":150},{"nctId":"NCT03095079","phase":"PHASE2","title":"Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-10","conditions":"Melanoma","enrollment":70},{"nctId":"NCT02579564","phase":"PHASE3","title":"Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients","status":"UNKNOWN","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2016-10","conditions":"Malignant Hydrothorax, Non Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT02804646","phase":"PHASE4","title":"Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Anhui Provincial Hospital","startDate":"2016-06","conditions":"Adenocarcinoma of Lung","enrollment":100},{"nctId":"NCT02665702","phase":"PHASE2","title":"Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2016-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":76},{"nctId":"NCT02520219","phase":"PHASE2","title":"Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study","status":"UNKNOWN","sponsor":"Nanjing NingQi Medicine Science and Technology Co., Ltd.","startDate":"2014-12","conditions":"Peripheral T-cell Lymphomas","enrollment":60},{"nctId":"NCT02513355","phase":"PHASE4","title":"Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research","status":"UNKNOWN","sponsor":"Nanjing NingQi Medicine Science and Technology Co., Ltd.","startDate":"2015-02","conditions":"Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT02513342","phase":"PHASE4","title":"Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma","status":"UNKNOWN","sponsor":"Nanjing NingQi Medicine Science and Technology Co., Ltd.","startDate":"2015-03","conditions":"Advanced Lung Squamous Carcinoma","enrollment":400},{"nctId":"NCT02497118","phase":"PHASE4","title":"Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2010-08","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT00842491","phase":"PHASE2","title":"Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Peking University","startDate":"2008-11","conditions":"Advanced Gastric Cancer","enrollment":45},{"nctId":"NCT02350361","phase":"PHASE2, PHASE3","title":"Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2014-01","conditions":"Lung Cancer","enrollment":60},{"nctId":"NCT02283476","phase":"PHASE3","title":"The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2014-11","conditions":"Lung Cancer","enrollment":200},{"nctId":"NCT01327235","phase":"PHASE2","title":"Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2011-03","conditions":"Malignant Pleural Effusion, Malignant Ascites","enrollment":336},{"nctId":"NCT01612286","phase":"PHASE2","title":"Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2012-05","conditions":"Nasopharyngeal Carcinoma","enrollment":30},{"nctId":"NCT02001168","phase":"PHASE3","title":"Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB","status":"UNKNOWN","sponsor":"Xinjiang Medical University","startDate":"2013-10","conditions":"Non-small Cell Lung Cancer","enrollment":392},{"nctId":"NCT01687439","phase":"PHASE2","title":"Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2008-12","conditions":"Non-small Cell Lung Cancer","enrollment":15},{"nctId":"NCT00595972","phase":"PHASE2","title":"Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2007-11","conditions":"Gastric Cancer","enrollment":25},{"nctId":"NCT01211002","phase":"PHASE4","title":"Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2010-10","conditions":"Non-small Cell Lung Cancer","enrollment":170},{"nctId":"NCT00657423","phase":"PHASE3","title":"Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2008-04","conditions":"Lung Neoplasms","enrollment":80},{"nctId":"NCT01124253","phase":"PHASE3","title":"Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2007-07","conditions":"Non-small Cell Lung Cancer","enrollment":250},{"nctId":"NCT00576914","phase":"PHASE3","title":"Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Sciences","startDate":"2007-06","conditions":"Non-small Cell Lung Cancer","enrollment":1108},{"nctId":"NCT01028729","phase":"PHASE4","title":"A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2009-09","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ENDOSTAR，cisplatin","genericName":"ENDOSTAR，cisplatin","companyName":"Jiangsu Simcere Pharmaceutical Co., Ltd.","companyId":"jiangsu-simcere-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation, used in combination with cisplatin chemotherapy to treat solid tumors. Used for Non-small cell lung cancer (in combination with cisplatin), Advanced solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}